Elekta AB (publ)

OM:EKTA B Stock Report

Market Cap: SEK 18.3b

Elekta Valuation

Is EKTA B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EKTA B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SEK 120.62
Fair Value
60.2% undervalued intrinsic discount
13
Number of Analysts

Below Fair Value: EKTA B (SEK48) is trading below our estimate of fair value (SEK120.62)

Significantly Below Fair Value: EKTA B is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EKTA B?

Key metric: As EKTA B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EKTA B. This is calculated by dividing EKTA B's market cap by their current earnings.
What is EKTA B's PE Ratio?
PE Ratio66.9x
EarningsSEK 274.00m
Market CapSEK 18.34b

Price to Earnings Ratio vs Peers

How does EKTA B's PE Ratio compare to its peers?

The above table shows the PE ratio for EKTA B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average33.3x
ARJO B Arjo
19.5x25.52%SEK 8.4b
GETI B Getinge
37.9x18.91%SEK 56.5b
SUS Surgical Science Sweden
47.6x42.64%SEK 4.4b
CEVI CellaVision
28.4x16.74%SEK 4.3b
EKTA B Elekta
66.9x28.57%SEK 18.3b

Price-To-Earnings vs Peers: EKTA B is expensive based on its Price-To-Earnings Ratio (66.9x) compared to the peer average (33.3x).

Price to Earnings Ratio vs Industry

How does EKTA B's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
EKTA B 66.9xIndustry Avg. 29.1xNo. of Companies11PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: EKTA B is expensive based on its Price-To-Earnings Ratio (66.9x) compared to the European Medical Equipment industry average (29.1x).

Price to Earnings Ratio vs Fair Ratio

What is EKTA B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EKTA B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio66.9x
Fair PE Ratio38x

Price-To-Earnings vs Fair Ratio: EKTA B is expensive based on its Price-To-Earnings Ratio (66.9x) compared to the estimated Fair Price-To-Earnings Ratio (38x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EKTA B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 48.00
SEK 53.69
+11.86%
31.69%SEK 108.00SEK 34.00n/a13
Oct ’26SEK 47.26
SEK 53.69
+13.61%
31.69%SEK 108.00SEK 34.00n/a13
Sep ’26SEK 47.96
SEK 55.31
+15.32%
28.99%SEK 108.00SEK 39.00n/a13
Aug ’26SEK 46.82
SEK 58.58
+25.11%
27.38%SEK 108.00SEK 39.00n/a13
Jul ’26SEK 49.08
SEK 58.58
+19.35%
27.38%SEK 108.00SEK 39.00n/a13
Jun ’26SEK 50.50
SEK 62.15
+23.08%
23.83%SEK 108.00SEK 47.00n/a13
May ’26SEK 49.00
SEK 67.07
+36.88%
21.04%SEK 108.00SEK 51.50n/a14
Apr ’26SEK 53.60
SEK 67.07
+25.13%
21.04%SEK 108.00SEK 51.50n/a14
Mar ’26SEK 59.05
SEK 69.86
+18.30%
27.36%SEK 127.00SEK 51.50n/a14
Feb ’26SEK 65.75
SEK 73.31
+11.49%
26.54%SEK 127.00SEK 51.50n/a13
Jan ’26SEK 61.15
SEK 73.38
+20.01%
27.12%SEK 127.00SEK 51.50n/a13
Dec ’25SEK 65.05
SEK 74.12
+13.94%
25.95%SEK 127.00SEK 57.00n/a13
Nov ’25SEK 64.30
SEK 76.36
+18.75%
23.64%SEK 127.00SEK 57.00n/a14
Oct ’25SEK 70.00
SEK 76.21
+8.88%
23.82%SEK 127.00SEK 57.00SEK 47.2614
Sep ’25SEK 70.10
SEK 76.69
+9.40%
24.66%SEK 127.00SEK 57.00SEK 47.9613
Aug ’25SEK 66.40
SEK 76.31
+14.92%
24.95%SEK 127.00SEK 57.00SEK 46.8213
Jul ’25SEK 65.90
SEK 76.38
+15.91%
24.74%SEK 127.00SEK 57.00SEK 49.0813
Jun ’25SEK 86.15
SEK 84.08
-2.40%
24.36%SEK 127.00SEK 57.00SEK 50.5012
May ’25SEK 79.20
SEK 83.42
+5.32%
24.47%SEK 127.00SEK 57.00SEK 49.0012
Apr ’25SEK 80.70
SEK 86.00
+6.57%
23.69%SEK 127.00SEK 57.00SEK 53.6012
Mar ’25SEK 77.84
SEK 86.33
+10.91%
23.35%SEK 127.00SEK 57.00SEK 59.0512
Feb ’25SEK 78.54
SEK 86.67
+10.35%
23.42%SEK 127.00SEK 57.00SEK 65.7512
Jan ’25SEK 82.32
SEK 84.73
+2.92%
23.30%SEK 127.00SEK 57.00SEK 61.1511
Dec ’24SEK 82.08
SEK 84.91
+3.45%
23.73%SEK 127.00SEK 57.00SEK 65.0511
Nov ’24SEK 75.82
SEK 82.00
+8.15%
26.19%SEK 127.00SEK 53.00SEK 64.3011
Oct ’24SEK 74.42
SEK 83.30
+11.93%
26.56%SEK 127.00SEK 53.00SEK 70.0010
SEK 53.69
Fair Value
10.6% undervalued intrinsic discount
13
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/13 13:18
End of Day Share Price 2025/10/13 00:00
Earnings2025/07/31
Annual Earnings2025/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Elekta AB (publ) is covered by 30 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Alexander KlebanBarclays
Sally TaylorBarclays